Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III
Executive Summary
Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.